SCHEMBL14730870

SCHEMBL14730870

O=S(=O)(CI)c1ccc2nccc(Cl)c2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1B Q9Y463 1/20 0.36
RIPK2 O43353 5/20 0.36
KCNH2 Q12809 2/20 0.36
PIK3CA P42336 1/20 0.35
NR4A2 P43354 1/20 0.35
CA9 Q16790 2/20 0.34
KDR P35968 2/20 0.34
RET P07949 1/20 0.34
MAPK14 Q16539 1/20 0.34
PKMYT1 Q99640 1/20 0.34
GAK O14976 1/20 0.33
AXL P30530 1/20 0.33
PRKCI P41743 1/20 0.33
HTR1A P08908 1/20 0.33
HTR1D P28221 1/20 0.33
HTR1B P28222 1/20 0.33
HTR2A P28223 1/20 0.33
HTR7 P34969 1/20 0.33
DRD3 P35462 1/20 0.33
HTR6 P50406 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2594512 0.86 CYP1A2 (0.40) DYRK1BRIPK2KCNH2PIK3CAKDR
SCHEMBL2594415 0.82 CYP2C9 (0.42) DYRK1BRIPK2KCNH2KDRRET
SCHEMBL602052 0.81 PNMT (0.36) DYRK1BRIPK2KCNH2PIK3CANR4A2
SCHEMBL2589369 0.81 DYRK1B (0.40) DYRK1BRIPK2KCNH2PIK3CANR4A2
SCHEMBL600488 0.80 RIPK2 (0.50) DYRK1BRIPK2KCNH2KDRRET
SCHEMBL17552284 0.80 ALDH1A1 (0.39) DYRK1BRIPK2KCNH2NR4A2CA9
SCHEMBL2595325 0.80 CA9 (0.50) NR4A2CA9CA12CA1CA2
SCHEMBL30880575 0.80 RIPK2 (0.50) DYRK1BRIPK2KCNH2KDRRET
SCHEMBL4005800 0.77 RIPK2 (0.42) DYRK1BRIPK2KCNH2PIK3CANR4A2
SCHEMBL14727530 0.76 VCAM1 (0.50) RIPK2KCNH2PIK3CAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130053375-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXO GROUP LIMITED 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053375-A1 AMINO-QUINOLINES AS KINASE INHIBITORS ABL1, MAP3K2, MAP4K2 DYRK1B 419/4885RIPK2 326/4885KCNH2 1159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.